Overview

A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

Status:
Not yet recruiting

Trial end date:
2024-03-30

Target enrollment:

Participant gender:

Summary

A multi-part study of ALG-097558 to evaluate safety, tolerability, pharmacokinetics and drug-drug interaction potential after single and multiple doses in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Aligos Therapeutics

Treatments:

Carbamazepine
Itraconazole
Midazolam